Myrobalan Therapeutics

Focus: Myrobalan Therapeutics is a Series A-stage biotech company focused on neurological and psychiatric therapies, operating from Medford, MA with an early-stage development focus.

Neurology Psychiatry

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Myrobalan Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Myrobalan Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Publications: 1 in PubMed

Hiring Trend

Stable

Help build intelligence for Myrobalan Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a Series A company in high-demand neurology/psychiatry therapeutic areas with significant unmet need
Chance to shape company culture and scientific direction during formative growth stage with direct impact on drug development strategy
Access to early-stage equity upside if company successfully advances pipeline and achieves future funding milestones

Watch Out For

No active clinical trials reported (0 Phase 1/2/3 programs) indicates very early discovery stage with uncertain de-risking timeline
Limited data on employee count, funding amount, or hiring momentum suggests restricted visibility into runway and growth trajectory
Zero current job openings signal no active hiring and potential constraints on near-term team expansion or career mobility

Generated by Claude from Myrobalan Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Based on last 4 crawl cycles

Research Publications(1)

Recent peer-reviewed publications with author affiliations at this company

A community-led initiative to de-risk and advance Parkinson's disease therapeutic targets.

NPJ Parkinson's disease

2025

PMID:40541945

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo